It was the consensus of the Working Group that the risks and benefits of endocrine therapy, either tamoxifen or an aromatase inhibitor after BCS, should be discussed with ER-positive DCIS patients. This evidence concerns the gene ESR1 and ductal breast carcinoma in situ.